Should not be used in patients with severe hepatic impairment. Use not recommended in patients with moderate hepatic impairment unless the benefit exceeds the risk. Reduce dose if used in patients with moderate hepatic impairment. Liver function tests should be closely monitored.
Skip to main content
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Trikafta (Vertex)
- INDICATIONS: Cystic fibrosis in patients aged 12 years and older who have at least one F508del mutation in the CFTR gene.
- CLASS: CFTR potentiator (ivacaftor), CFTR protein corrector (elexacaftor), CFTR protein corrector (tezacaftor)
- HALF-LIFE: 30 hours (elexacaftor); 17 hours (tezacaftor); 15 hours (ivacaftor)
- FDA APPROVAL DATE: 10/21/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP3A inducers: rifampin, rifabutin, phenobarbital, carbamazepine, phenytoin, and St. Johns wort (Hypericum perforatum) , CYP3A inhibitors: ketoconazole, itraconazole, posaconazole, voriconazole, telithromycin clarithromycin, fluconazole, erythromycin, grapefruit juice - PREGNANCY: Limited and incomplete human data from clinical trials on the use of elexacaftor, tezacaftor and ivacaftor in pregnant women to inform a drug-associated risk.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 12/30/2025
